User login
While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to control successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.
This fourth eNewsletter in the series, entitled Effect of Non–Insulin-Based Glucose-Lowering Therapies on Cardiovascular Outcomes in Patients With Type 2 Diabetes, was written by Szymon L. Wiernek, MD, PhD, and Matthew A. Cavender, MD, MPH. It presents an overview of commonly used non–insulin-based glucose-lowering drugs in the context of cardiovascular disease risk. The basic mechanisms of action for each pharmacotherapeutic class and the effects of these medications on cardiovascular events are discussed so that physicians can make informed treatment decisions
Click here to read the supplement
Department of Medicine University of North Carolina-Chapel Hill
Chapel Hill, NC
Department of Medicine University of North Carolina-Chapel Hill
Chapel Hill, NC
While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to control successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.
This fourth eNewsletter in the series, entitled Effect of Non–Insulin-Based Glucose-Lowering Therapies on Cardiovascular Outcomes in Patients With Type 2 Diabetes, was written by Szymon L. Wiernek, MD, PhD, and Matthew A. Cavender, MD, MPH. It presents an overview of commonly used non–insulin-based glucose-lowering drugs in the context of cardiovascular disease risk. The basic mechanisms of action for each pharmacotherapeutic class and the effects of these medications on cardiovascular events are discussed so that physicians can make informed treatment decisions
Click here to read the supplement
Department of Medicine University of North Carolina-Chapel Hill
Chapel Hill, NC
Department of Medicine University of North Carolina-Chapel Hill
Chapel Hill, NC
While type 2 diabetes (T2D) is commonly seen in primary care, it is difficult to control successfully over time. This series offers brief eNewsletters written by clinical experts that are designed to assist in the clinical management of patients with T2D.
This fourth eNewsletter in the series, entitled Effect of Non–Insulin-Based Glucose-Lowering Therapies on Cardiovascular Outcomes in Patients With Type 2 Diabetes, was written by Szymon L. Wiernek, MD, PhD, and Matthew A. Cavender, MD, MPH. It presents an overview of commonly used non–insulin-based glucose-lowering drugs in the context of cardiovascular disease risk. The basic mechanisms of action for each pharmacotherapeutic class and the effects of these medications on cardiovascular events are discussed so that physicians can make informed treatment decisions
Click here to read the supplement
Department of Medicine University of North Carolina-Chapel Hill
Chapel Hill, NC
Department of Medicine University of North Carolina-Chapel Hill
Chapel Hill, NC
